Non-interventional Study of Avelumab in the Treatment of Urothelial Cancer - The AVENUE NIS - AB 82/21 of AUO First-line Maintenance Therapy in Adult Patients with locally advanced or metastatic Urothelial Cancer who are progression-free after platinum-based Chemotherapy

被引:0
|
作者
不详
机构
来源
UROLOGIE | 2023年 / 62卷 / 06期
关键词
D O I
10.1007/s00120-023-02120-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:672 / 673
页数:2
相关论文
共 50 条
  • [21] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
    Ciardiello, F.
    Bang, Y-J.
    Bendell, J.
    Cervantes, A.
    Brachmann, R.
    Zhang, K.
    Raponi, M.
    Farin, H.
    Shen, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 265 - 265
  • [22] Bevacizumab Combined with Platinum-Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients
    Sehouli, Jalid
    Mustea, Alexander
    Oskay-Ozcelik, Guelten
    Keller, Maren
    Richter, Rolf
    Tome, Oliver
    Woopen, Hannah
    Sommer-Joos, Ann-Katrin
    Grabowski, Jacek P. P.
    Armbrust, Robert
    Wimberger, Pauline
    CANCERS, 2021, 13 (19)
  • [23] First line therapy for locally advanced or metastatic urothelial cancer: A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)—AB 58/17 of the AUO
    Rexer H.
    Ohlmann C.-H.
    Gschwend J.
    Der Urologe, 2017, 56 (10): : 1331 - 1332
  • [24] Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy
    Shah, Amishi Yogesh
    Gao, Jianjun
    Rezazadeh, Arash
    Cole, Suzanne
    Jain, Rohit K.
    Stevenson, Alex
    Fyvie, Gayle
    Gaw, Nina Jane
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
    Vignani, F.
    Hamzaj, A.
    De Giorgi, U.
    Tambaro, R.
    Basso, U.
    Gamba, T.
    Ermacora, P.
    Santini, D.
    Capacci, S.
    Casadei, C.
    Pignata, S.
    Bimbatti, D.
    Giannatempo, P.
    Atzori, F.
    Cavanna, L.
    Veccia, A.
    Scandurra, G.
    Doni, L.
    Aieta, M.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S607 - S607
  • [26] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
    Powles, T.
    Grivas, P.
    Aragon-Ching, J. B.
    Faroun, Y.
    Kessler, E. R.
    Tomita, Y.
    Chakrabarti, D.
    Laliberte, R. J.
    Shnaidman, M.
    Petrylak, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Brachmann, Rainer Karl
    Zhang, Yuting
    Raponi, Mitch
    Farin, Heinrich
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Relationship between 6-and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Moshier, Erin
    Sonpavde, Guru
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    CANCER, 2013, 119 (16) : 3020 - 3026
  • [29] Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
    Liang, Weiming
    Wang, Zhijing
    Huang, Zhilong
    Huang, Yanping
    Li, Chunyan
    Liang, Yiwen
    Huang, Miaoyan
    Zhang, Duo
    Li, Chenchen
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [30] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Brachmann, Rainer Karl
    Zhang, Yuting
    Raponi, Mitch
    Farin, Heinrich
    Lin, Shen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)